Investigation of solid lipid nanoparticles as oral delivery of Paclitaxel for enhanced absorption

N.A.

Makale detayları

Investigation of solid lipid nanoparticles as oral delivery of Paclitaxel for enhanced absorption

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Delivery Technologies

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 3, pp.781-796

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346646

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Paclitaxel is an anticancer drug that has poor oral bioavailability 10 because of its poor solubility in aqueous medium, poor permeability, and is a substrate of poly-glycoprotein and CYP450 metabolism. The current study intends to create Paclitaxel-loaded solid lipid nanoparticles SLNs to overcome these limitations. The nanoparticles were formulated through an emulsification-solvent evaporation method and freeze-dried. To optimize the nanoparticle formulation, the box-behnken design was adopted. The final formulation had a particle size of 190 nm with 88.79 drug entrapment. The in-vitro release study for 24 hr showed a 1.6-fold increase in drug release in the dissolution of paclitaxel from SLNs in comparison to drug suspension. A 2.4-fold increase in bioavailability of the drug in-vivo was obtained compared to the commercial formulation. Thus, a promising carrier for PTX was developed that could increase its efficiency and alleviate the dose-dependent side effects.

 Paclitaxel is an anticancer drug that has poor oral bioavailability 10 because of its poor solubility in aqueous medium, poor permeability, and is a substrate of poly-glycoprotein and CYP450 metabolism. The current study intends to create Paclitaxel-loaded solid lipid nanoparticles SLNs to overcome these limitations. The nanoparticles were formulated through an emulsification-solvent evaporation method and freeze-dried. To optimize the nanoparticle formulation, the box-behnken design was adopted. The final formulation had a particle size of 190 nm with 88.79 drug entrapment. The in-vitro release study for 24 hr showed a 1.6-fold increase in drug release in the dissolution of paclitaxel from SLNs in comparison to drug suspension. A 2.4-fold increase in bioavailability of the drug in-vivo was obtained compared to the commercial formulation. Thus, a promising carrier for PTX was developed that could increase its efficiency and alleviate the dose-dependent side effects.

 Paclitaxel is an anticancer drug that has poor oral bioavailability 10 because of its poor solubility in aqueous medium, poor permeability, and is a substrate of poly-glycoprotein and CYP450 metabolism. The current study intends to create Paclitaxel-loaded solid lipid nanoparticles SLNs to overcome these limitations. The nanoparticles were formulated through an emulsification-solvent evaporation method and freeze-dried. To optimize the nanoparticle formulation, the box-behnken design was adopted. The final formulation had a particle size of 190 nm with 88.79 drug entrapment. The in-vitro release study for 24 hr showed a 1.6-fold increase in drug release in the dissolution of paclitaxel from SLNs in comparison to drug suspension. A 2.4-fold increase in bioavailability of the drug in-vivo was obtained compared to the commercial formulation. Thus, a promising carrier for PTX was developed that could increase its efficiency and alleviate the dose-dependent side effects.

 Paclitaxel is an anticancer drug that has poor oral bioavailability 10 because of its poor solubility in aqueous medium, poor permeability, and is a substrate of poly-glycoprotein and CYP450 metabolism. The current study intends to create Paclitaxel-loaded solid lipid nanoparticles SLNs to overcome these limitations. The nanoparticles were formulated through an emulsification-solvent evaporation method and freeze-dried. To optimize the nanoparticle formulation, the box-behnken design was adopted. The final formulation had a particle size of 190 nm with 88.79 drug entrapment. The in-vitro release study for 24 hr showed a 1.6-fold increase in drug release in the dissolution of paclitaxel from SLNs in comparison to drug suspension. A 2.4-fold increase in bioavailability of the drug in-vivo was obtained compared to the commercial formulation. Thus, a promising carrier for PTX was developed that could increase its efficiency and alleviate the dose-dependent side effects.

Makale detayları

Investigation of solid lipid nanoparticles as oral delivery of Paclitaxel for enhanced absorption

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Delivery Technologies

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 3, pp.781-796

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346646

pISSN:

2630-6344

Paclitaxel

Intestinal permeability

solubility

M-cell uptake

Sayı

Makale detayları

Investigation of solid lipid nanoparticles as oral delivery of Paclitaxel for enhanced absorption

Yazarlar: N.A.

Yayıncı: Marmara University

Ana Başlıklar: Pharmaceutical Delivery Technologies

Dergi: Journal of Research in Pharmacy Vol.28 Issue 3, pp.781-796

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001346646

pISSN: 2630-6344

Paclitaxel

Intestinal permeability

solubility

M-cell uptake

Sayı

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Delivery Technologies

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 3, pp.781-796

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346646

pISSN:

2630-6344